Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA. Fagerlin A, et al. Among authors: hayes df. Breast Cancer Res Treat. 2010 Feb;119(3):613-20. doi: 10.1007/s10549-009-0618-4. Breast Cancer Res Treat. 2010. PMID: 19908143 Free PMC article. Clinical Trial.
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P; Droloxifene 301 Study Group. Buzdar A, et al. Breast Cancer Res Treat. 2002 May;73(2):161-75. doi: 10.1023/a:1015229630260. Breast Cancer Res Treat. 2002. PMID: 12088118 Clinical Trial.
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ. Henry NL, et al. Among authors: hayes df. Breast Cancer Res Treat. 2008 Sep;111(2):365-72. doi: 10.1007/s10549-007-9774-6. Epub 2007 Oct 6. Breast Cancer Res Treat. 2008. PMID: 17922185 Free PMC article. Clinical Trial.
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators. Henry NL, et al. Among authors: hayes df. Breast Cancer Res Treat. 2009 Oct;117(3):571-5. doi: 10.1007/s10549-009-0309-1. Epub 2009 Jan 20. Breast Cancer Res Treat. 2009. PMID: 19153830 Free PMC article. Clinical Trial.
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V; COBRA investigators. Rae JM, et al. Among authors: hayes df. Pharmacogenomics J. 2009 Aug;9(4):258-64. doi: 10.1038/tpj.2009.14. Epub 2009 May 5. Pharmacogenomics J. 2009. PMID: 19421167 Free PMC article. Clinical Trial.
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA. Fagerlin A, et al. Among authors: hayes df. Breast Cancer Res Treat. 2011 Jun;127(3):681-8. doi: 10.1007/s10549-011-1450-1. Epub 2011 Mar 26. Breast Cancer Res Treat. 2011. PMID: 21442198 Free PMC article. Clinical Trial.
483 results